Stammdaten
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Unternehmen & Branche
| Name | Anbio Biotechnology |
|---|---|
| Ticker | NNNN |
| CIK | 0001982708 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Instruments & Supplies |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | G0367B105 |
|---|---|
| ISIN | USG0367B1055 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,20 Mrd. USD |
| Beta | 8,49 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 25,763 | 0 | 25,763 | 774,693 | Neu | +100,0% | |
| UBS Group AG | 2,849 | 0 | 2,849 | 85,669 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 1,000 | 0 | 1,000 | 30,070 | Neu | +100,0% | |
| WELLS FARGO & COMPANY/MN | 100 | 0 | 100 | 3,007 | Neu | +100,0% | |
| MORGAN STANLEY | 28 | 0 | 28 | 842 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-30 | 1.776 | 23,92 | 42.482 |
| 2026-03-27 | 436 | 23,20 | 10.115 |
| 2026-03-26 | 948 | 23,76 | 22.524 |
| 2026-03-24 | 3 | 22,87 | 69 |
| 2026-03-23 | 1.754 | 23,54 | 41.289 |
| 2026-03-20 | 1.841 | 22,17 | 40.815 |
| 2026-03-19 | 1.104 | 21,00 | 23.184 |
| 2026-03-18 | 460 | 21,50 | 9.890 |
| 2026-03-17 | 428 | 21,82 | 9.339 |
| 2026-03-16 | 1.839 | 20,51 | 37.718 |
| 2026-03-13 | 2.578 | 22,54 | 58.108 |
| 2026-03-12 | 714 | 21,91 | 15.644 |
| 2026-03-11 | 68 | 20,93 | 1.423 |
| 2026-03-10 | 1.702 | 22,21 | 37.801 |
| 2026-03-09 | 2.357 | 22,89 | 53.952 |
| 2026-03-05 | 407 | 24,22 | 9.858 |
| 2026-03-04 | 1.084 | 23,11 | 25.051 |
| 2026-03-03 | 666 | 22,91 | 15.258 |
| 2026-03-02 | 428 | 25,76 | 11.025 |
| 2026-02-27 | 2.376 | 27,55 | 65.459 |
| 2026-02-26 | 2.608 | 25,96 | 67.704 |
| 2026-02-25 | 309 | 24,47 | 7.561 |
| 2026-02-24 | 416 | 24,62 | 10.242 |
| 2026-02-23 | 644 | 24,70 | 15.907 |
| 2026-02-20 | 977 | 25,47 | 24.884 |
| 2026-02-19 | 6.805 | 26,19 | 178.223 |
| 2026-02-18 | 3.134 | 23,50 | 73.649 |
| 2026-02-17 | 6.300 | 24,20 | 152.460 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 25,763 | 774,693 | 86.63 |
| UBS Group AG | 2,849 | 85,669 | 9.58 |
| BNP PARIBAS FINANCIAL MARKETS | 1,000 | 30,070 | 3.36 |
| WELLS FARGO & COMPANY/MN | 100 | 3,007 | 0.34 |
| MORGAN STANLEY | 28 | 842 | 0.09 |